-
1
-
-
2942615257
-
Antiangiogenic basis of low-dose metronomic chemotherapy
-
Kerbel RS, Kamen BA. Antiangiogenic basis of low-dose metronomic chemotherapy. Nat Rev Cancer 2004;4:423-36.
-
(2004)
Nat Rev Cancer
, vol.4
, pp. 423-436
-
-
Kerbel, R.S.1
Kamen, B.A.2
-
2
-
-
21744437791
-
Repopulation of cancer cells during therapy: An important cause of treatment failure
-
Kim JJ, Tannock IF. Repopulation of cancer cells during therapy: an important cause of treatment failure. Nat Rev Cancer 2005;5:516-25.
-
(2005)
Nat Rev Cancer
, vol.5
, pp. 516-525
-
-
Kim, J.J.1
Tannock, I.F.2
-
3
-
-
50349097617
-
Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: Implications for antiangiogenic drugs as chemosensitizing agents
-
Shaked Y, Henke E, Roodhart JM, Mancuso P, Langenberg MH, Colleoni M, et al. Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents. Cancer Cell 2008;14:263-73.
-
(2008)
Cancer Cell
, vol.14
, pp. 263-273
-
-
Shaked, Y.1
Henke, E.2
Roodhart, J.M.3
Mancuso, P.4
Langenberg, M.H.5
Colleoni, M.6
-
4
-
-
34547617338
-
Antiangiogenic strategies on defense: On the possibility of blocking rebounds by the tumor vasculature after chemotherapy
-
Shaked Y, Kerbel RS. Antiangiogenic strategies on defense: on the possibility of blocking rebounds by the tumor vasculature after chemotherapy. Cancer Res 2007;67:7055-8.
-
(2007)
Cancer Res
, vol.67
, pp. 7055-7058
-
-
Shaked, Y.1
Kerbel, R.S.2
-
5
-
-
33749005405
-
Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors
-
Shaked Y, Ciarrocchi A, Franco M, Lee CR, Man S, Cheung AM, et al. Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors. Science 2006;313:1785-7.
-
(2006)
Science
, vol.313
, pp. 1785-1787
-
-
Shaked, Y.1
Ciarrocchi, A.2
Franco, M.3
Lee, C.R.4
Man, S.5
Cheung, A.M.6
-
6
-
-
79955517032
-
TIE2-expressing macrophages limit the therapeutic efficacy of the vascular-disrupting agent combretastatin A4 phosphate in mice
-
Welford AF, Biziato D, Coffelt SB, Nucera S, Fisher M, Pucci F, et al. TIE2-expressing macrophages limit the therapeutic efficacy of the vascular-disrupting agent combretastatin A4 phosphate in mice. J Clin Invest 2011;121:1969-73.
-
(2011)
J Clin Invest
, vol.121
, pp. 1969-1973
-
-
Welford, A.F.1
Biziato, D.2
Coffelt, S.B.3
Nucera, S.4
Fisher, M.5
Pucci, F.6
-
7
-
-
84941779973
-
Perivascular M2 macrophages stimulate tumor relapse after chemotherapy
-
Hughes R, Qian BZ, Rowan C, Muthana M, Keklikoglou I, Olson OC, et al. Perivascular M2 macrophages stimulate tumor relapse after chemotherapy. Cancer Res 2015;75:3479-91.
-
(2015)
Cancer Res
, vol.75
, pp. 3479-3491
-
-
Hughes, R.1
Qian, B.Z.2
Rowan, C.3
Muthana, M.4
Keklikoglou, I.5
Olson, O.C.6
-
8
-
-
81155126054
-
Chemotherapy enhances metastasis formation via VEGFR-1-expressing endothelial cells
-
Daenen LG, Roodhart JM, van Amersfoort M, Dehnad M, Roessingh W, Ulfman LH, et al. Chemotherapy enhances metastasis formation via VEGFR-1-expressing endothelial cells. Cancer Res 2011;71:6976-85.
-
(2011)
Cancer Res
, vol.71
, pp. 6976-6985
-
-
Daenen, L.G.1
Roodhart, J.M.2
Van Amersfoort, M.3
Dehnad, M.4
Roessingh, W.5
Ulfman, L.H.6
-
9
-
-
81155132194
-
Host response to short-term, single-agent chemotherapy induces matrix metalloproteinase-9 expression and accelerates metastasis in mice
-
Gingis-Velitski S, Loven D, Benayoun L, Munster M, Bril R, Voloshin T, et al. Host response to short-term, single-agent chemotherapy induces matrix metalloproteinase-9 expression and accelerates metastasis in mice. Cancer Res 2011;71:6986-96.
-
(2011)
Cancer Res
, vol.71
, pp. 6986-6996
-
-
Gingis-Velitski, S.1
Loven, D.2
Benayoun, L.3
Munster, M.4
Bril, R.5
Voloshin, T.6
-
10
-
-
0034087691
-
Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity
-
Klement G, Baruchel S, Rak J, Man S, Clark K, Hicklin D, et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 2000;105:R15-24.
-
(2000)
J Clin Invest
, vol.105
, pp. R15-R24
-
-
Klement, G.1
Baruchel, S.2
Rak, J.3
Man, S.4
Clark, K.5
Hicklin, D.6
-
11
-
-
0034032882
-
Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer
-
Browder T, Butterfield CE, Kraling BM, Marshall B, O'Reilly MS, Folkman J. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 2000;60:1878-86.
-
(2000)
Cancer Res
, vol.60
, pp. 1878-1886
-
-
Browder, T.1
Butterfield, C.E.2
Kraling, B.M.3
Marshall, B.4
O'Reilly, M.S.5
Folkman, J.6
-
12
-
-
0034048358
-
Less is more, regularly: Metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice
-
Hanahan D, Bergers G, Bergsland E. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest 2000;105:1045-7.
-
(2000)
J Clin Invest
, vol.105
, pp. 1045-1047
-
-
Hanahan, D.1
Bergers, G.2
Bergsland, E.3
-
13
-
-
27644436870
-
The optimal biological dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity
-
Shaked Y, Emmengger U, Man S, Cervi D, Bertolini F, Ben-David Y, et al. The optimal biological dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity. Blood 2005;106:3058-61.
-
(2005)
Blood
, vol.106
, pp. 3058-3061
-
-
Shaked, Y.1
Emmengger, U.2
Man, S.3
Cervi, D.4
Bertolini, F.5
Ben-David, Y.6
-
14
-
-
84860815596
-
Metronomic cyclophosphamide treatment in metastasized breast cancer patients: Immunological effects and clinical outcome
-
Ge Y, Domschke C, Stoiber N, Schott S, Heil J, Rom J, et al. Metronomic cyclophosphamide treatment in metastasized breast cancer patients: immunological effects and clinical outcome. Cancer Immunol Immunother 2012;61:353-62.
-
(2012)
Cancer Immunol Immunother
, vol.61
, pp. 353-362
-
-
Ge, Y.1
Domschke, C.2
Stoiber, N.3
Schott, S.4
Heil, J.5
Rom, J.6
-
15
-
-
84876678701
-
Low-dose gemcitabine depletes regulatory T cells and improves survival in the orthotopic Panc02 model of pancreatic cancer
-
Shevchenko I, Karakhanova S, Soltek S, Link J, Bayry J, Werner J, et al. Low-dose gemcitabine depletes regulatory T cells and improves survival in the orthotopic Panc02 model of pancreatic cancer. Int J Cancer 2013;133: 98-107.
-
(2013)
Int J Cancer
, vol.133
, pp. 98-107
-
-
Shevchenko, I.1
Karakhanova, S.2
Soltek, S.3
Link, J.4
Bayry, J.5
Werner, J.6
-
16
-
-
33847368549
-
Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients
-
Ghiringhelli F, Menard C, Puig PE, Ladoire S, Roux S, Martin F, et al. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother 2007;56:641-8.
-
(2007)
Cancer Immunol Immunother
, vol.56
, pp. 641-648
-
-
Ghiringhelli, F.1
Menard, C.2
Puig, P.E.3
Ladoire, S.4
Roux, S.5
Martin, F.6
-
17
-
-
84857723974
-
VEGF receptor inhibitors block the ability of metronomically dosed cyclophosphamide to activate innate immunity-induced tumor regression
-
Doloff JC, Waxman DJ. VEGF receptor inhibitors block the ability of metronomically dosed cyclophosphamide to activate innate immunity-induced tumor regression. Cancer Res 2012;72:1103-15.
-
(2012)
Cancer Res
, vol.72
, pp. 1103-1115
-
-
Doloff, J.C.1
Waxman, D.J.2
-
18
-
-
84900395848
-
Intermittent metronomic drug schedule is essential for activating antitumor innate immunity and tumor xenograft regression
-
Chen CS, Doloff JC, Waxman DJ. Intermittent metronomic drug schedule is essential for activating antitumor innate immunity and tumor xenograft regression. Neoplasia 2014;16:84-96.
-
(2014)
Neoplasia
, vol.16
, pp. 84-96
-
-
Chen, C.S.1
Doloff, J.C.2
Waxman, D.J.3
-
19
-
-
34248550985
-
Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors
-
Folkins C, Man S, Xu P, Shaked Y, Hicklin DJ, Kerbel RS. Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors. Cancer Res 2007;67:3560-4.
-
(2007)
Cancer Res
, vol.67
, pp. 3560-3564
-
-
Folkins, C.1
Man, S.2
Xu, P.3
Shaked, Y.4
Hicklin, D.J.5
Kerbel, R.S.6
-
20
-
-
77950815444
-
Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer
-
Hashimoto K, Man S, Xu P, Cruz-Munoz W, Tang T, Kumar R, et al. Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer. Mol Cancer Ther 2010;9:996-1006.
-
(2010)
Mol Cancer Ther
, vol.9
, pp. 996-1006
-
-
Hashimoto, K.1
Man, S.2
Xu, P.3
Cruz-Munoz, W.4
Tang, T.5
Kumar, R.6
-
21
-
-
84927618369
-
Postsurgical adjuvant or metastatic renal cell carcinoma therapy models reveal potent antitumor activity of metronomic oral topotecan with pazopanib
-
Jedeszko C, Paez-Ribes M, Di Desidero T, Man S, Lee CR, Xu P, et al. Postsurgical adjuvant or metastatic renal cell carcinoma therapy models reveal potent antitumor activity of metronomic oral topotecan with pazopanib. Sci Transl Med 2015;7:282ra50.
-
(2015)
Sci Transl Med
, vol.7
-
-
Jedeszko, C.1
Paez-Ribes, M.2
Di Desidero, T.3
Man, S.4
Lee, C.R.5
Xu, P.6
-
22
-
-
84907394550
-
Anti-Bv8 antibody and metronomic gemcitabine improve pancreatic adenocarcinoma treatment outcome following weekly gemcitabine therapy
-
Hasnis E, Alishekevitz D, Gingis-Veltski S, Bril R, Fremder E, Voloshin T, et al. Anti-Bv8 antibody and metronomic gemcitabine improve pancreatic adenocarcinoma treatment outcome following weekly gemcitabine therapy. Neoplasia 2014;16:501-10.
-
(2014)
Neoplasia
, vol.16
, pp. 501-510
-
-
Hasnis, E.1
Alishekevitz, D.2
Gingis-Veltski, S.3
Bril, R.4
Fremder, E.5
Voloshin, T.6
-
23
-
-
84929514070
-
Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): A phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group
-
Simkens LH, van Tinteren H, May A, ten Tije AJ, Creemers GJ, Loosveld OJ, et al. Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group. Lancet 2015;385:1843-52.
-
(2015)
Lancet
, vol.385
, pp. 1843-1852
-
-
Simkens, L.H.1
Van Tinteren, H.2
May, A.3
Ten Tije, A.J.4
Creemers, G.J.5
Loosveld, O.J.6
-
24
-
-
84873086527
-
Low-dose metronomic chemotherapy: From past experience to new paradigms in the treatment of cancer
-
Loven D, Hasnis E, Bertolini F, Shaked Y. Low-dose metronomic chemotherapy: from past experience to new paradigms in the treatment of cancer. Drug Discov Today 2013;18:193-201.
-
(2013)
Drug Discov Today
, vol.18
, pp. 193-201
-
-
Loven, D.1
Hasnis, E.2
Bertolini, F.3
Shaked, Y.4
-
25
-
-
54449099774
-
Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer
-
Dellapasqua S, Bertolini F, Bagnardi V, Campagnoli E, Scarano E, Torrisi R, et al. Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer. J Clin Oncol 2008;26:4899-905.
-
(2008)
J Clin Oncol
, vol.26
, pp. 4899-4905
-
-
Dellapasqua, S.1
Bertolini, F.2
Bagnardi, V.3
Campagnoli, E.4
Scarano, E.5
Torrisi, R.6
-
26
-
-
33645744835
-
Highly efficacious non-toxic treatment for advanced metastatic breast cancer using combination UFT-cyclophosphamide metronomic chemotherapy
-
Munoz R, Man S, Shaked Y, Lee C, Wong J, Francia G, et al. Highly efficacious non-toxic treatment for advanced metastatic breast cancer using combination UFT-cyclophosphamide metronomic chemotherapy. Cancer Res 2006;66:3386-91.
-
(2006)
Cancer Res
, vol.66
, pp. 3386-3391
-
-
Munoz, R.1
Man, S.2
Shaked, Y.3
Lee, C.4
Wong, J.5
Francia, G.6
-
28
-
-
81255135837
-
Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes
-
DeRose YS, Wang G, Lin YC, Bernard PS, Buys SS, Ebbert MT, et al. Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes. Nat Med 2011;17:1514-20.
-
(2011)
Nat Med
, vol.17
, pp. 1514-1520
-
-
DeRose, Y.S.1
Wang, G.2
Lin, Y.C.3
Bernard, P.S.4
Buys, S.S.5
Ebbert, M.T.6
-
29
-
-
84938657323
-
Potential pro-invasive or metastatic effects of preclinical antiangiogenic therapy are prevented by concurrent chemotherapy
-
Paez-Ribes M, Man S, Xu P, Kerbel RS. Potential pro-invasive or metastatic effects of preclinical antiangiogenic therapy are prevented by concurrent chemotherapy. Clin Cancer Res 2015;21:5488-98.
-
(2015)
Clin Cancer Res
, vol.21
, pp. 5488-5498
-
-
Paez-Ribes, M.1
Man, S.2
Xu, P.3
Kerbel, R.S.4
-
30
-
-
84944463082
-
Dequalinium blocks macrophage-induced metastasis following local radiation
-
Timaner M, Bril R, Kaidar-Person O, Rachman-Tzemah C, Alishekevitz D, Kotsofruk R, et al. Dequalinium blocks macrophage-induced metastasis following local radiation. Oncotarget 2015;6:27537-54.
-
(2015)
Oncotarget
, vol.6
, pp. 27537-27554
-
-
Timaner, M.1
Bril, R.2
Kaidar-Person, O.3
Rachman-Tzemah, C.4
Alishekevitz, D.5
Kotsofruk, R.6
-
31
-
-
84872084645
-
Metronomic oral topotecan prolongs survival and reduces liver metastasis in improved preclinical orthotopic and adjuvant therapy colon cancer models
-
Hackl C, Man S, Francia G, Milsom C, Xu P, Kerbel RS. Metronomic oral topotecan prolongs survival and reduces liver metastasis in improved preclinical orthotopic and adjuvant therapy colon cancer models. Gut 2013;62:259-71.
-
(2013)
Gut
, vol.62
, pp. 259-271
-
-
Hackl, C.1
Man, S.2
Francia, G.3
Milsom, C.4
Xu, P.5
Kerbel, R.S.6
-
32
-
-
0037093209
-
Antitumor and anti-angiogenic effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water
-
Man S, Bocci G, Francia G, Green S, Jothy S, Bergers G, et al. Antitumor and anti-angiogenic effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water. Cancer Res 2002;62:2731-5.
-
(2002)
Cancer Res
, vol.62
, pp. 2731-2735
-
-
Man, S.1
Bocci, G.2
Francia, G.3
Green, S.4
Jothy, S.5
Bergers, G.6
-
33
-
-
84942082818
-
Blocking IL-1beta pathway following paclitaxel chemotherapy slightly inhibits primary tumor growth but promotes spontaneous metastasis
-
Voloshin T, Alishekevitz D, Kaneti L, Miller V, Isakov E, Kaplanov I, et al. Blocking IL-1beta pathway following paclitaxel chemotherapy slightly inhibits primary tumor growth but promotes spontaneous metastasis. Mol Cancer Ther 2015;14:1385-94.
-
(2015)
Mol Cancer Ther
, vol.14
, pp. 1385-1394
-
-
Voloshin, T.1
Alishekevitz, D.2
Kaneti, L.3
Miller, V.4
Isakov, E.5
Kaplanov, I.6
-
34
-
-
80054768631
-
Extracting a cellular hierarchy from high-dimensional cytometry data with SPADE
-
Qiu P, Simonds EF, Bendall SC, Gibbs KD Jr, Bruggner RV, Linderman MD, et al. Extracting a cellular hierarchy from high-dimensional cytometry data with SPADE. Nat Biotechnol 2011;29:886-91.
-
(2011)
Nat Biotechnol
, vol.29
, pp. 886-891
-
-
Qiu, P.1
Simonds, E.F.2
Bendall, S.C.3
Gibbs, K.D.4
Bruggner, R.V.5
Linderman, M.D.6
-
35
-
-
79955750055
-
Single-cell mass cytometry of differential immune and drug responses across a human hematopoietic continuum
-
Bendall SC, Simonds EF, Qiu P, Amir el AD, Krutzik PO, Finck R, et al. Single-cell mass cytometry of differential immune and drug responses across a human hematopoietic continuum. Science 2011;332:687-96.
-
(2011)
Science
, vol.332
, pp. 687-696
-
-
Bendall, S.C.1
Simonds, E.F.2
Qiu, P.3
Amir El, A.D.4
Krutzik, P.O.5
Finck, R.6
-
37
-
-
84879601793
-
The host immunological response to cancer therapy: An emerging concept in tumor biology
-
Voloshin T, Voest EE, Shaked Y. The host immunological response to cancer therapy: an emerging concept in tumor biology. Exp Cell Res 2013;319:1687-95.
-
(2013)
Exp Cell Res
, vol.319
, pp. 1687-1695
-
-
Voloshin, T.1
Voest, E.E.2
Shaked, Y.3
-
38
-
-
84939986130
-
Host effects contributing to cancer therapy resistance
-
Katz OB, Shaked Y. Host effects contributing to cancer therapy resistance. Drug Resist Updat 2015;19:33-42.
-
(2015)
Drug Resist Updat
, vol.19
, pp. 33-42
-
-
Katz, O.B.1
Shaked, Y.2
-
39
-
-
84973866691
-
Balancing efficacy of and host immune responses to cancer therapy: The yin and yang effects
-
Apr 26. [Epub ahead of print]
-
Shaked Y. Balancing efficacy of and host immune responses to cancer therapy: the yin and yang effects. Nat Rev Clin Oncol. 2016 Apr 26. [Epub ahead of print].
-
(2016)
Nat Rev Clin Oncol
-
-
Shaked, Y.1
-
40
-
-
0041589524
-
Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells
-
Bertolini F, Paul S, Mancuso P, Monestiroli S, Gobbi A, Shaked Y, et al. Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Res 2003;63:4342-6.
-
(2003)
Cancer Res
, vol.63
, pp. 4342-4346
-
-
Bertolini, F.1
Paul, S.2
Mancuso, P.3
Monestiroli, S.4
Gobbi, A.5
Shaked, Y.6
-
41
-
-
1642414466
-
Selective anti-endothelial effects of protracted low-dose BAL-9504, a novel geranylgeranyl-transferase inhibitor
-
Bocci G, Danesi R, Del Tacca M, Kerbel RS. Selective anti-endothelial effects of protracted low-dose BAL-9504, a novel geranylgeranyl-transferase inhibitor. Eur J Pharmacol 2003;477:17-21.
-
(2003)
Eur J Pharmacol
, vol.477
, pp. 17-21
-
-
Bocci, G.1
Danesi, R.2
Del Tacca, M.3
Kerbel, R.S.4
-
42
-
-
84874116665
-
Metronomic chemotherapy with low-dose cyclophosphamide plus gemcitabine can induce anti-tumor T cell immunity in vivo
-
Tongu M, Harashima N, Monma H, Inao T, Yamada T, Kawauchi H, et al. Metronomic chemotherapy with low-dose cyclophosphamide plus gemcitabine can induce anti-tumor T cell immunity in vivo. Cancer Immunol Immunother 2013;62:383-91.
-
(2013)
Cancer Immunol Immunother
, vol.62
, pp. 383-391
-
-
Tongu, M.1
Harashima, N.2
Monma, H.3
Inao, T.4
Yamada, T.5
Kawauchi, H.6
|